ABOUT HOTH THERAPEUTICS
Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.
BIOLEXA PLATFORM OVERVIEW
BioLexa platform technology is a patented topical agent that combines a chelating agent with an antibiotic in a proprietary formula, to fight bacterial infections across multiple platforms. The current formulation has applicability in the areas of:
- Aesthetic dermatology
- Surgical site infections
- Chronic wound care
- Chronic diabetic wound care
Hoth Therapeutics seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes upcoming events, presentations and financial documents.
Patent Covers Proprietary Compositions for Eczema Treatment NEW YORK, NY, December 4, 2017 /PRNewswire/ Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from...
Applications for the BioLexa platform from Hoth Therapeutics